Eterna Therapeutics Inc. (ERNA)

2.2200 +0.2400 (+12.12%) At close: 04:00PM EDT

Eterna Therapeutics Inc.

1035 Cambridge Street
Suite 18A
Cambridge, MA 02141
United States
212 582 1199
https://eternatx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Sandra M. Gurrola	Principal Financial & Accounting Officer and Senior VP of Finance	305.88k	N/A	1967
Mr. Sanjeev Luther	CEO, President & Director	N/A	N/A	1962
Ms. Dorothy J. Clarke	General Counsel & Director	N/A	N/A	1966

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Corporate Governance

Eterna Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.